SCHEMBL16245589

SCHEMBL16245589

CCOC(=O)CCCCOc1cccc(Nc2nc(Cl)ncc2[N+](=O)[O-])c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 2/20 0.52
▸ CYSLTR2 Q9NS75 2/20 0.43
▸ CYSLTR1 Q9Y271 2/20 0.43
▸ JAK2 O60674 1/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ EGFR P00533 3/20 0.42
▸ GSK3B P49841 2/20 0.41
▸ AURKA O14965 1/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ MAPT P10636 3/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ BCL6 P41182 1/20 0.39
▸ BCOR Q6W2J9 1/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245532 0.89 PIN1 (0.53) PIN1CYSLTR2CYSLTR1MEN1KMT2A
SCHEMBL16245543 0.86 PIN1 (0.54) PIN1CYSLTR2CYSLTR1MEN1KMT2A
SCHEMBL4520873 0.79 PIN1 (0.67) PIN1JAK2MEN1KMT2AGSK3B
SCHEMBL16245545 0.76 PIN1 (0.50) PIN1MEN1KMT2AEGFRGSK3B
SCHEMBL19958511 0.75 PIN1 (0.72) PIN1MEN1KMT2AEGFRGSK3B
SCHEMBL19877901 0.75 PIN1 (0.71) PIN1JAK2MEN1KMT2AEGFR
SCHEMBL16012720 0.75 PIN1 (0.58) PIN1MEN1KMT2AEGFRGSK3B
SCHEMBL16245555 0.74 P2RX3 (0.44) CYSLTR2CYSLTR1AURKAMAPTKDM4E
SCHEMBL656001 0.73 PIN1 (0.72) PIN1MEN1KMT2AGSK3BAURKA
SCHEMBL18869322 0.73 P2RX3 (0.43) CYSLTR2CYSLTR1JAK2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
EP-2994471-A1 MACROCYCLES AS KINASE INHIBITORS Merck Patent GmbH (DE) 2016-03-16 — — EP disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS EIF2AK4, CDK2, CDK1 PIN1 1347/4885CYSLTR2 2472/4885CYSLTR1 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback